BioCentury | Apr 30, 2019
Distillery Therapeutics
RUNX1, RUNX3, CBFB and PMP22 as targets for neurofibromatosis
...DISEASE CATEGORY: Cancer INDICATION: Neurofibromatosis Cell culture and mouse studies suggest promoting PMP22 expression, dual RUNX1/RUNX3...
...neurofibroma Schwann cells, overexpression of the RUNX1/RUNX3 target PMP22 decreased cell growth compared with normal PMP22...
...RUNX proteins decreased tumor growth compared with vehicle. Next steps could include identifying and testing PMP22...
...neurofibroma Schwann cells, overexpression of the RUNX1/RUNX3 target PMP22 decreased cell growth compared with normal PMP22...
...RUNX proteins decreased tumor growth compared with vehicle. Next steps could include identifying and testing PMP22...